

## DAFTAR PUSTAKA

- Alshatwi, A.A., Ramesh, E., Periasamy, V.S., Subash-Babu, P., 2013. The apoptotic effect of hesperetin on human cervical cancer cells is mediated through cell cycle arrest, death receptor, and mitochondrial pathways. *Fundam. Clin. Pharmacol.* 27, 581–592.
- Arteaga, C.L., Sliwkowski, M.X., Osborne, C.K., Perez, E.A., Puglisi, F., Gianni, L., 2012. Treatment of HER2-positive breast cancer: current status and future perspectives. *Nat. Rev. Clin. Oncol.* 9, 16–32.
- Bandyopadhyay, A., Wang, L., Agyin, J., Tang, Y., Lin, S., Yeh, I.-T., De, K., Sun, L.-Z., 2010. Doxorubicin in Combination with a Small TGF $\beta$  Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models. *PLoS ONE* 5, e10365.
- Bertoli, C., Skotheim, J.M., de Bruin, R.A.M., 2013. Control of cell cycle transcription during G1 and S phases. *Nat. Rev. Mol. Cell Biol.* 14, 518–528.
- Bid, H.K., Roberts, R.D., Manchanda, P.K., Houghton, P.J., 2013. RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. *Mol. Cancer Ther.* 12, 1925–1934.
- Chandrika, B.B., Stephan, M., Kumar, T.R.S., Sabu, A., Haridas, M., 2016. Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors. *Life Sci.* 160, 47–56.
- Cho, J., 2006. Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. *Arch. Pharm. Res.* 29, 699–706.
- Cho, Y.B., Lee, W.Y., Song, S.Y., Shin, H.J., Yun, S.H., Chun, H.-K., 2007. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. *Hum. Pathol.* 38, 1603–1610.
- Choi, E.J., 2007. Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: involvement of CDK4 and p21. *Nutr. Cancer* 59, 115–119.
- Choi, E.J., Kim, G.D., Chee, K.-M., Kim, G.-H., 2006. Effects of hesperetin on vessel structure formation in mouse embryonic stem (mES) cells. *Nutrition* 22, 947–951.

- Comşa, Ş., Cîmpean, A.M., Raica, M., 2015. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. *Anticancer Res.* 35, 3147–3154.
- Darzynkiewicz, Z., Bedner, E., Smolewski, P., 2001. Flow cytometry in analysis of cell cycle and apoptosis. *Semin. Hematol.* 38, 179–193.
- De, P., Carlson, J.H., Jepperson, T., Willis, S., Leyland-Jones, B., Dey, N., 2017. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers. *Oncotarget* 8, 3072–3103.
- De Potter, C.R., 1994. The neu-oncogene: more than a prognostic indicator? *Hum. Pathol.* 25, 1264–1268.
- Dehay, C., Kennedy, H., 2007. Cell-cycle control and cortical development. *Nat. Rev. Neurosci.* 8, 438–450.
- Elmore, S., 2007. Apoptosis: a review of programmed cell death. *Toxicol. Pathol.* 35, 495–516.
- El-Sayyad, H.I., Ismail, M.F., Shalaby, F.M., Abou-El-Magd, R.F., Gaur, R.L., Fernando, A., Raj, M.H., Ouhtit, A., 2009. Histopathological effects of cisplatin, doxorubicin and 5-fluorouracil (5-FU) on the liver of male albino rats. *Int J Biol Sci* 5, 466–473.
- Fesik, S.W., 2005. Promoting apoptosis as a strategy for cancer drug discovery. *Nat. Rev. Cancer* 5, 876–885. doi:10.1038/nrc1736
- Fulda, S., Debatin, K.-M., 2006. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. *Oncogene* 25, 4798–4811.
- Geiger, T.R., Peeper, D.S., 2009. Metastasis mechanisms. *Biochim. Biophys. Acta BBA - Rev. Cancer* 1796, 293–308.
- Gerber, D.E., 2008. Targeted therapies: a new generation of cancer treatments. *Am. Fam. Physician* 77, 311–319.
- Hanahan, D., Weinberg, R.A., 2011. Hallmarks of Cancer: The Next Generation. *Cell* 144, 646–674.
- Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., Sakuragi, N., 2014. Apoptosis and molecular targeting therapy in cancer. *BioMed Res. Int.* 2014, 150845.

- Iqbal, N., Iqbal, N., 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Mol. Biol. Int.* 2014, 852748.
- Kenny, H.A., Kaur, S., Coussens, L.M., Lengyel, E., 2008. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. *J. Clin. Invest.* 118, 1367–1379.
- Kim, G.D., 2014. Hesperetin Inhibits Vascular Formation by Suppressing of the PI3K/AKT, ERK, and p38 MAPK Signaling Pathways. *Prev. Nutr. Food Sci.* 19, 299–306.
- Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G.B., Mendelsohn, J., Fan, Z., 2003. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. *Oncogene* 22, 3205–3212.
- Krishnamurti, U., Silverman, J.F., 2014. HER2 in breast cancer: A review and update. *ResearchGate* 21, 100–7.
- Leber, M.F., Efferth, T., 2009. Molecular principles of cancer invasion and metastasis (review). *Int. J. Oncol.* 34, 881–895.
- Lee, A.V., Oesterreich, S., Davidson, N.E., 2015. MCF-7 cells--changing the course of breast cancer research and care for 45 years. *J. Natl. Cancer Inst.* 107.
- Liang, J., Slingerland, J.M., 2003. Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression. *Cell Cycle* 2, 336–342.
- Lim, S., Kaldis, P., 2013. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. *Dev. Camb. Engl.* 140, 3079–3093.
- Mehner, C., Hockla, A., Miller, E., Ran, S., Radisky, D.C., Radisky, E.S., 2014. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. *Oncotarget* 5, 2736–2749.
- Meiyanto, E., Hermawan, A., Anindyajati, A., 2012. Natural Products for Cancer-Targeted Therapy: Citrus Flavonoids as Potent Chemopreventive Agents. *Asian Pac. J. Cancer Prev.* 13, 427–436.
- Minotti, G., 2004. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. *Pharmacol. Rev.* 56, 185–229.

- Nunez, R., 2001. DNA measurement and cell cycle analysis by flow cytometry. *Curr. Issues Mol. Biol.* 3, 67–70.
- Ouyang, L., Shi, Z., Zhao, S., Wang, F.-T., Zhou, T.-T., Liu, B., Bao, J.-K., 2012. Programmed Cell Death Pathways in Cancer: A Review of Apoptosis, Autophagy and Programmed Necrosis. *ResearchGate* 45.
- Palit, S., Kar, S., Sharma, G., Das, P.K., 2015. Hesperetin Induces Apoptosis in Breast Carcinoma by Triggering Accumulation of ROS and Activation of ASK1/JNK Pathway. *J. Cell. Physiol.* 230, 1729–1739.
- Patrick Reynolds, C., Maurer, B., 2005. Evaluating Response to Antineoplastic Drug Combinations in Tissue Culture Models, in: Blumenthal, R. (Ed.), *Chemosensitivity, Methods in Molecular Medicine™*. Humana Press, pp. 173–183.
- Rebucci, M., Michiels, C., 2013. Molecular aspects of cancer cell resistance to chemotherapy. *Biochem. Pharmacol.* 85, 1219–1226.
- Rimawi, M.F., Schiff, R., Osborne, C.K., 2015. Targeting HER2 for the Treatment of Breast Cancer. *Annu. Rev. Med.* 66, 111–128.
- Sarmoko, P, D.D.P., Susidarti, R.A., Nugroho, A.E., Meiyanto, E., 2014. Increasing Sensitivity of MCF-7/Dox Cells Towards Doxorubicin by Hesperetin Through Suppression Of P-Glycoprotein Expression. *Indones. J. Pharm.* 25, 84. 4
- Schulz, W.A., 2005. *Molecular Biology of Human Cancer*. Springer, USA.
- Shan, Y.-Q., Ying, R.-C., Zhou, C.-H., Zhu, A.-K., Ye, J., Zhu, W., Ju, T.-F., Jin, H.-C., 2015. MMP-9 is increased in the pathogenesis of gastric cancer by the mediation of HER2. *Cancer Gene Ther.* 22, 101–107.
- Sherr, C.J., Bartek, J., 2017. Cell Cycle–Targeted Cancer Therapies. *Annu. Rev. Cancer Biol.* 1, null.
- Siegel, R.L., Miller, K.D., Jemal, A., 2016. Cancer statistics, 2016. *CA. Cancer J. Clin.* 66, 7–30. doi:10.3322/caac.21332
- Su, Z., Yang, Z., Xu, Y., Chen, Y., Yu, Q., 2015. Apoptosis, autophagy, necroptosis, and cancer metastasis. *Mol. Cancer* 14.
- Tacar, O., Sriamornsak, P., Dass, C.R., 2013. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. *J. Pharm. Pharmacol.* 65, 157–170. doi:10.1111/j.2042-7158.2012.01567.x

- Taylor, W., Stark, G., 2001. Regulation of the G2/M transition by p53. *Publ. Online* 05 April 2001
- Thorn, C.F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T.E., Altman, R.B., 2011. Doxorubicin pathways: pharmacodynamics and adverse effects. *Pharmacogenet. Genomics* 21, 440–446.
- Trivedi, P.P., Kushwaha, S., Tripathi, D.N., Jena, G.B., 2011. Cardioprotective Effects of Hesperetin against Doxorubicin-Induced Oxidative Stress and DNA Damage in Rat. *Cardiovasc. Toxicol.* 11, 215–225.
- Vermeulen, K., Bockstaele, D.R.V., Berneman, Z.N., 2003. Vermeulen K, Van Bockstaele DR, Berneman ZN The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. *Cell Prolif* 36: 131-149. *ResearchGate* 36, 131–49.
- Wang, S.E., Shin, I., Wu, F.Y., Friedman, D.B., Arteaga, C.L., 2006. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. *Cancer Res.* 66, 9591–9600.
- Yang, F., Teves, S.S., Kemp, C.J., Henikoff, S., 2014. Doxorubicin, DNA torsion, and chromatin dynamics. *Biochim. Biophys. Acta* 1845, 84–89.
- Yang, Y., Wolfram, J., Boom, K., Fang, X., Shen, H., Ferrari, M., 2013. Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. *Cell Biochem. Funct.* 31, 374–379.
- Yang, Y., Wolfram, J., Shen, H., Fang, X., Ferrari, M., 2012. Hesperetin: an Inhibitor of the Transforming Growth Factor- $\beta$  (TGF- $\beta$ ) Signaling Pathway. *Eur. J. Med. Chem.* 58, 390–395.
- Yu, D., Hung, M.C., 2000. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. *Oncogene* 19, 6115–6121.
- Zhao, S., Ohara, S., Kanno, Y., Midorikawa, Y., Nakayama, M., Makimura, M., Park, Y., Inouye, Y., 2013. HER2 overexpression-mediated inflammatory signaling enhances mammosphere formation through up-regulation of aryl hydrocarbon receptor transcription. *Cancer Lett.* 330, 41–48.